IQVIA HOLDINGS INC. (IQV) Form 8-K — Oct 27, 2026
IQVIA reported Q3 2026 revenue of $4,428 million, up 8.0% year-over-year, with GAAP net income of $350 million and adjusted diluted EPS of $3.34, up 11.3%. CEO Ari Bousbib called it a record quarter with results exceeding the high end of expectations. R&D Solutions net new bookings hit $3.2 billion, up 15% YoY (book-to-bill 1.2x) — the strongest clinical quarterly bookings since 2022. R&DS backlog stands at $32.6 billion after a $2.1 billion adjustment for inactive trials, which had no impact on results or guidance.
Key figures
- Eps
- 2.1
- Revenue
- 4428000000
- Guidance
- FY2026 revenue $17,350M-$17,500M; Adjusted EBITDA $4,025M-$4,055M; Adjusted Diluted EPS $12.90-$13.00 (raised)
- Net Income
- 350000000
- Total Debt
- 16067000000
- Revenue Yoy
- 8.0%
- Cash Position
- 2249000000
- Net debt
- $13,818 million
- Rnd backlog
- $32.6 billion
- Ytd revenue
- $12,947 million, up 8.4%
- Adjusted eps
- 3.34
- Book to bill
- 1.2x
- Ltm bookings
- $11.7 billion, up 14% YoY
- Free cash flow
- 667000000
- Adjusted ebitda
- $1,032 million, up 8.7% YoY
- Adjusted eps yoy
- 11.3%
- Net new bookings
- $3.2 billion, up 15% YoY
- Ai agents deployed
- over 400
- Backlog adjustment
- $2.1 billion (inactive trials review)
- Net leverage ratio
- 3.45x
- Adjusted net income
- 557000000
- Operating cash flow
- 825000000
- Rnd solutions revenue
- $2,639M, up 8.7% YoY
- Commercial solutions revenue
- $1,789M, up 6.9% YoY
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.